Barinthus Bio Sets 0.111 Exchange Ratio, Delisting Sept 3 as Clywedog Merger Nears Close
BRNS sits 18% above its 52-week low of $0.512 on light trading volume (0.1× avg).
Summary
Barinthus Bio finalized the exchange ratio for its merger with Clywedog and confirmed its ADSs will delist from Nasdaq on September 3, 2026, with the combined company to trade as CLYD.
Key Events · M&A and Partnerships · BRNS
-
Scheme Exchange Ratio Set at 0.111
The Board determined the Scheme Exchange Ratio at 0.111, ensuring the price of Topco common stock issued in exchange for Scheme Shares meets Nasdaq's minimum price requirement.
-
ADS Delisting Set for September 3
Trading of Barinthus Bio ADSs on Nasdaq is expected to halt prior to market open on September 3, 2026, with Form 25 and Form 15 filings to follow for delisting and deregistration.
-
Combined Company to Trade as CLYD
Following completion of the merger, Topco will be renamed Clywedog Therapeutics Holdings, Inc. and its common stock will list on Nasdaq under the ticker symbol CLYD.
-
High Court Hearing on September 1
The scheme of arrangement application will be heard before a High Court Judge at the Royal Courts of Justice in London on September 1, 2026, the final regulatory step before effectiveness.
Analysis · BRNS · Life Sciences
The final step in the all-stock merger with Clywedog Therapeutics is now in place: Barinthus Bio has set the Scheme Exchange Ratio at 0.111 and confirmed that its ADSs will delist from Nasdaq effective September 3, 2026. The combined company will trade under the ticker CLYD. The exchange ratio was chosen to ensure the new Topco shares meet Nasdaq's minimum price requirement, a critical condition for the listing. The High Court hearing on September 1 is the last regulatory hurdle before the scheme becomes effective.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRNS was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.6M. The 52-week trading range was $0.51 to $1.83. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.